Skip to main content
Premium Trial:

Request an Annual Quote

2bPrecise, Q-State Biosciences Partner on Precision Medicine

NEW YORK – Q-State Biosciences and the 2bPrecise unit of Allscripts Healthcare Solutions said today that they have agreed to collaborate on building clinical-genomic datasets to support the practice of precision medicine.

With their partnership, the two technology vendors hope to produce insights that care providers can apply to clinical practice and that pharmaceutical companies can use to develop novel therapies. 

Pittsburgh-based 2bPrecise will contribute its cloud-based technology platform that integrates genomic data into clinical workflows. Q-State, of Cambridge, Massachusetts, is offering whole-genome and whole-exome sequencing, as well as transcriptomics analysis and phenotyping services to the partnership.

"This partnership facilitates healthcare innovation that enables precision medicine and genetically based clinical care on a transformative scale," 2bPrecise Founder and CEO Assaf Halevy said in a statement.

"Genomic data holds the power to evolve the entire healthcare industry. Today, patients' genetic information enables not only diagnoses, but also systematic identification of disease targets and synthesis of new genetically targeted medicines," added Q-State CEO Matthew Fox.

Terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.